Two Aryl Rings Or Aryl Ring Systems Bonded Directly To The Same Acyclic Carbon Patents (Class 514/648)
-
Patent number: 8846766Abstract: Provided is a drug substance and a method of treating an ailment comprising administering an oral dose of a drug product comprising the drug substance wherein the drug substance comprises an organic acid addition salt of methadone. The organic acid addition salt is selected from the group consisting of pamoate and xinafoate wherein the drug substance is bioavailable under gastrointestinal administration but is not bioavailable under administration at a mucosal membrane other than gastrointestinal or release from a depot injectable product.Type: GrantFiled: July 29, 2013Date of Patent: September 30, 2014Assignee: Pisgah Laboratories, Inc.Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol, Michael L. English
-
Patent number: 8840923Abstract: Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release pharmaceutical formulations.Type: GrantFiled: December 23, 2008Date of Patent: September 23, 2014Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla, Leonardo Marchitto, Lorella Ragni
-
Publication number: 20140228375Abstract: The present invention involves new and original sigma receptors ligands: (Mono-or dialkylaminoalkyl)-?-butyrolactones, their analogues aminotetrahydroturanes, the (1-adamantyl) benzene alkylamines, the N,N Dialkyl ?-[(adamantyl-1)benzyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or-alkyl phenylamines, their enantiomers or diastereoisomers, their pharmaceutically acceptable salts and Quinacrine Me-thylene blue, Asteinizole and their relative analogues with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with prototypical anti-cancer, antimetastatic and antiviral activities associated with antagonism of the neuropatic pain and, at very low doses, with cytoprotective and cytoregenerative activity against the cytodegenerative diseases.Type: ApplicationFiled: March 12, 2014Publication date: August 14, 2014Applicant: Anavex Life Sciences Corp.Inventor: Alexandre Vamvakides
-
Publication number: 20140200277Abstract: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.Type: ApplicationFiled: January 27, 2014Publication date: July 17, 2014Applicants: The University of North Carolina at Chapel Hill, The United States of America as represented by the Department of Veterans Affairs, The Regents of the University of CaliforniaInventors: Frank M. Longo, Stephen M. Massa
-
Publication number: 20140200271Abstract: Memantine compositions and methods of use are described herein. In some embodiments, the compositions comprise memantine and an absorption enhancer, or memantine and an elimination enhancer, or memantine and an absorption enhancer and an elimination enhancer.Type: ApplicationFiled: July 2, 2013Publication date: July 17, 2014Applicant: Cerecor, Inc.Inventors: Blake Paterson, Mark Ginski, Brendan Canning
-
Patent number: 8778397Abstract: A method of making a pharmaceutical composition containing tolterodine L-tartrate stabilized against degradation with an acid. Acid-stabilized tolterodine L-tartrate may be used as an active ingredient in various types of immediate release and controlled release dosage forms, including tablets, capsules, and beads.Type: GrantFiled: June 11, 2013Date of Patent: July 15, 2014Assignee: Mylan, Inc.Inventors: David T. Rossi, Boyong Li, James Paul McCall
-
Patent number: 8765817Abstract: Embodiments of the present invention comprises a compound of formula I or its enantiomer, diastereomer, stereoisomer or its pharmaceutically acceptable salt, methods of use and methods of synthesis.Type: GrantFiled: January 4, 2013Date of Patent: July 1, 2014Assignee: Arrowhead Center, Inc.Inventors: Jeffrey Arterburn, Charles B. Shuster
-
Patent number: 8765816Abstract: Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention.Type: GrantFiled: April 6, 2010Date of Patent: July 1, 2014Assignee: Cognition Therapeutics, Inc.Inventors: Gilbert M. Rishton, Susan Catalano
-
Publication number: 20140178374Abstract: The disclosure relates to BAX activators and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.Type: ApplicationFiled: August 17, 2012Publication date: June 26, 2014Applicants: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, EMORY UNIVERSITYInventors: Xingming Deng, Jia Zhou, Chunyong Ding
-
Publication number: 20140179796Abstract: The technology described herein relates to compositions, kits, assays, systems and methods relating to breast cancer and the treatment thereof.Type: ApplicationFiled: December 18, 2013Publication date: June 26, 2014Applicant: THOMAS JEFFERSON UNIVERSITYInventors: Agnieszka WITKIEWICZ, Erik KNUDSEN, Gordon SCHWARTZ
-
Patent number: 8754121Abstract: Methods for treating melanoma in a subject in need thereof are disclosed. The method comprises administering to the subject a composition comprising a therapeutically effective amount of deoxyelephantopin or an analogue thereof; and a pharmaceutically acceptable carrier. Methods of inhibiting proliferation, migration and/or metastasis of melanoma cells in a subject in need thereof are also disclosed. Also disclosed are methods for reducing side effects of an anti-cancer agent in a subject in need thereof.Type: GrantFiled: August 19, 2011Date of Patent: June 17, 2014Assignee: Academia SinicaInventors: Lie-Fen Shyur, Wen-Wan Chao, Ya-Wen Cheng
-
Patent number: 8748476Abstract: The invention provides the use of darifenacin, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the reduction of urgency in patients suffering from overactive bladder.Type: GrantFiled: March 4, 2009Date of Patent: June 10, 2014Assignee: Warner Chilcott Company, LLCInventors: Enrico Colli, Paul Quinn, Dzelal Serdarevic, Larence Howard Skillern
-
Publication number: 20140142067Abstract: The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto.Type: ApplicationFiled: November 12, 2013Publication date: May 22, 2014Applicant: BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITYInventors: Aviv GAZIT, Shimon SLAVIN, Esther PRIEL, Sara YITZCHAK
-
Publication number: 20140112995Abstract: The present invention relates to pharmaceutical compositions comprising multilayered multiple units and processes for the preparation thereof.Type: ApplicationFiled: December 23, 2013Publication date: April 24, 2014Applicant: RANBAXY LABORATORIES LIMITEDInventors: Murali Krishna BHAVARISETTI, Kanwarpreet Singh BAKSHI, Sreekanth NARRAVULA, Romi Barat SINGH, Ajay Kumar SINGLA
-
Patent number: 8703823Abstract: Compositions, methods and kits are provided for the treatment of migraines. The compositions, methods and kits include an effective dose of trimethobenzamide and an ethanolamine antihistamine that, when administered to an individual suffering from migraine headaches, will alleviate symptoms associated with the migraine headaches. Compositions, methods, and kits for the treatment of migraines include pharmaceutical compositions of trimethobenzamide and diphenhydramine.Type: GrantFiled: September 16, 2008Date of Patent: April 22, 2014Inventor: Foad Salehani
-
Publication number: 20140093560Abstract: The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism.Type: ApplicationFiled: December 3, 2013Publication date: April 3, 2014Applicant: Repros Therapeutics Inc.Inventor: Joseph S. Podolski
-
Publication number: 20140094492Abstract: Derivatives of sulindac that lack cyclooxygenase inhibitory activity are provided along with pharmaceutical compositions containing them and use for treatment or prevention of cancer. The derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided.Type: ApplicationFiled: March 30, 2012Publication date: April 3, 2014Applicant: Southern Research InstituteInventors: Robert Reynolds, Bini Mathew, Gary A. Piazza
-
Publication number: 20140088155Abstract: The present invention relates to a method of treating psychiatric symptoms in a subject having a NMDA receptor and a NE receptor which includes administering d-methadone, d-methadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, pharmaceutically acceptable salts thereof, or mixtures thereof, to the subject under conditions effective for the substance to bind to the NMDA receptor and NE receptor of the subject.Type: ApplicationFiled: March 14, 2013Publication date: March 27, 2014Inventors: Paolo L. Manfredi, Charles E. Inturrisi
-
Publication number: 20140088059Abstract: The invention provides compositions and methods for the prevention, diagnosis, or treatment of conditions affecting breast tissue. The compositions can include one or more therapeutic agents or diagnostic agents, and an effective carrier. The composition can be specifically adapted for transdermal permeation through the mammary papilla, areola, or a combination thereof, and into underlying breast tissue.Type: ApplicationFiled: July 15, 2013Publication date: March 27, 2014Inventors: Omathanu P Perumal, Kaushalkumar Dave, Chandradhar Dwivedi, Sreevidy Santha
-
Patent number: 8674136Abstract: Aromatic butan-2-ol compounds, preparation methods for making the compounds, and uses of the compounds are provided. Specifically, the compound of Formula I, or an optical isomer, racemate, diastereomer, pharmaceutically acceptable salt, or solvate thereof, is provided, where each of the substituents is defined. In addition, a pharmaceutical composition containing the compound, and the use of the compound in manufacture of a medicament for the treatment and/or prophylaxis of a disease or disorder caused by tubercle bacillus infection, is provided.Type: GrantFiled: May 16, 2011Date of Patent: March 18, 2014Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Wu Zhong, Ping Liu, Junhai Xiao, Zhibing Zheng, Yunde Xie, Guoming Zhao, Xiaokui Wang, Lili Wang, Xingzhou Li, Xinbo Zhou
-
Publication number: 20140072571Abstract: Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.Type: ApplicationFiled: March 11, 2013Publication date: March 13, 2014Applicant: TETHYS BIOSCIENCE, INC.Inventors: Mickey S. Urdea, Michael P. McKenna, Patrick A. Arensdorf
-
Publication number: 20140073611Abstract: The disclosure relates to a platform of using zebrafish in screening candidates for treating and/or preventing myopia and keratoconus disease. The disclosure is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the disclosure uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and/or the regulation of eyeball size. These drugs are potential candidates for treating myopia and/or keratoconus disease.Type: ApplicationFiled: May 21, 2013Publication date: March 13, 2014Applicant: National Taiwan UniversityInventors: I-Jong Wang, Wei-Ting Ho, Ting-Hsuan Chiang, I-Tsen Lin
-
Patent number: 8668932Abstract: A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.Type: GrantFiled: March 18, 2011Date of Patent: March 11, 2014Assignee: Andrx Pharmaceuticals, LLCInventors: Manesh Dixit, Xiu-Xiu Cheng, Avinash Nangia, Chin Ming Chen
-
Publication number: 20140044774Abstract: The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising an H1 antihistamine and/or a salt thereof, and optionally, a hostile biophysical environment and/or a nitric oxide donor. In some cases, the composition may be stabilized using a combination of a stabilization polymer (such as xanthan gum, KELTROL® BT and/or KELTROL® RD), propylene glycol, and a polysorbate surfactant such as Polysorbate 20, which combination unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.Type: ApplicationFiled: December 29, 2011Publication date: February 13, 2014Applicant: Strategic Science & Technologies, LLCInventor: Eric T. Fossel
-
Patent number: 8642576Abstract: Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.Type: GrantFiled: August 29, 2012Date of Patent: February 4, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Mark E. Salvati, Heather Finlay, Bang-Chi Chen, Lalgudi S. Harikrishnan, Ji Jiang, James A. Johnson, Muthoni G. Kamau, R. Michael Lawrence, Jianqing Li, John Lloyd, Michael M. Miller, Zulan Pi, Jennifer X. Qiao, Richard A. Rampulla, Jacques Y. Roberge, Tammy C. Wang, Yufeng Wang, Wu Yang
-
Patent number: 8642662Abstract: Methods of preparing, and compositions comprising, derivatives of (?)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.Type: GrantFiled: May 25, 2012Date of Patent: February 4, 2014Assignee: Sunovion Pharmaceuticals Inc.Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Nandkumar N. Bhongle
-
Patent number: 8642078Abstract: A sustained release pharmaceutical composition comprising coating comprising at least one water-insoluble permeable polymer and at least one water soluble polymer and homogenous cores containing only tolterodine or a salt thereof and microcrystalline cellulose is described.Type: GrantFiled: March 29, 2007Date of Patent: February 4, 2014Assignee: Lek Pharmaceuticals, D.D.Inventors: Igor Legen, Polonca Kuhar
-
Publication number: 20140018435Abstract: The invention provides for compositions for transdermal delivery of a therapeutic agent associated with a surface modified poly(amidoamine) PAMAM dendrimer, wherein the surface modified dendrimer increased skin penetration of the therapeutic agent. The invention particularly provides for compositions and methods for transdermal delivery of anticancer and chemo-preventive agents.Type: ApplicationFiled: May 30, 2013Publication date: January 16, 2014Inventors: Seungpyo Hong, Robert Chatterton, Seema Khan, Oukseub Lee, Yang Yang
-
Publication number: 20140005196Abstract: This invention offers an effective method of inhibiting the expression of apolipoprotein E by mammalian cells. Apolipoprotein E is a protein that plays a significant role in the development of Alzheimer's Disease in humans. The method comprises administering an effective amount of a triarylmethyl amine compound having the general formula: wherein the R1 group may comprise acyclic amines and aliphatic amines. The R2 group may comprise one of three aryl varieties: aryl, substituted aryl, or heterocycle. Triarylamine compounds inhibit apolipoprotein E expression in mammalian cells. In one aspect of the invention the mammalian cells may be human cells, and more specifically may be human brain cells.Type: ApplicationFiled: June 28, 2012Publication date: January 2, 2014Applicants: California State University Fullerton, California State University FresnoInventors: Santanu Maitra, Nilay Patel
-
Patent number: 8609736Abstract: The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto.Type: GrantFiled: June 4, 2008Date of Patent: December 17, 2013Assignee: Ben-Gurion University of the Negev Research and Development AuthorityInventors: Aviv Gazit, Shimon Slavin, Esther Priel, Sara Yitzchak
-
Patent number: 8604245Abstract: The present invention relates to a novel class of tri-aryl compounds, compositions comprising the same and processes for the preparation thereof.Type: GrantFiled: June 3, 2008Date of Patent: December 10, 2013Assignee: Ben-Gurion University of the Negev Research and Development AuthorityInventors: Esther Priel, Aviv Gazit, Shimon Slavin, Sara Yitzchak
-
Publication number: 20130324481Abstract: This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably ?-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.Type: ApplicationFiled: August 9, 2013Publication date: December 5, 2013Applicant: Ramscor, Inc.Inventors: Vernon G. Wong, Louis L. Wood
-
Patent number: 8586061Abstract: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.Type: GrantFiled: December 22, 2009Date of Patent: November 19, 2013Assignee: JDS Therapeutics, LLCInventor: James R. Komorowski
-
Publication number: 20130296346Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, prodrug or solvate thereof, a method of synthesis of said compounds, pharmaceutical compositions comprising them and their use as a medicament for treating inflammatory diseases.Type: ApplicationFiled: November 22, 2011Publication date: November 7, 2013Applicant: Faes Farma, S.A.Inventors: Rosa Rodes Solanes, Neftali Garcia Dominguez, Beatriz Lopez Ortega, Melchor Alvarez De Mon Soto, Antonio De La Hera Martinez, Ana Munoz Munoz, Francisco Ledo Gomez
-
Publication number: 20130296438Abstract: Methods and compositions that can be used to identify and characterize inhibitors of K-ras localization to the plasma membrane and in doing so inhibit the signal transduction of K-ras. Such compositions can be used to treat K-ras mediated disorders, such as cancer.Type: ApplicationFiled: April 30, 2013Publication date: November 7, 2013Inventors: John F. HANCOCK, Dharini VAN DER HOEVEN, Kwang-Jin CHO
-
Publication number: 20130296439Abstract: A method of making a pharmaceutical composition containing tolterodine L-tartrate stabilized against degradation with an acid. Acid-stabilized tolterodine L-tartrate may be used as an active ingredient in various types of immediate release and controlled release dosage forms, including tablets, capsules, and beads.Type: ApplicationFiled: June 11, 2013Publication date: November 7, 2013Inventors: David T. Rossi, Boyong Li, James Paul McCall
-
Publication number: 20130281491Abstract: The invention provides pharmaceutical compositions for the sublingual delivery of opioids. The invention also provides delivery devices adapted for sublingual delivery of such compositions.Type: ApplicationFiled: June 29, 2011Publication date: October 24, 2013Applicant: LondonPharma Ltd.Inventor: Elizabeth Anita Ross
-
Publication number: 20130272963Abstract: A cholesterol efflux assay probe formulation having a core comprised of a biocompatible hydrophobic material at least partially coated with a sphingomyelin/cholesterol layer, methods of making and methods of using are described.Type: ApplicationFiled: April 12, 2013Publication date: October 17, 2013Applicant: The Ohio State UniversityInventors: Sanjay Rajagopalan, Markus A. Badgeley, Andrei Maiseyeu
-
Publication number: 20130274280Abstract: This invention provides an oral pharmaceutical composition comprising a physiologically tolerable gelled oil-in-water emulsion containing a drug of abuse.Type: ApplicationFiled: April 11, 2011Publication date: October 17, 2013Applicant: AYANDA GROUP ASInventors: Kurt Ingar Draget, Ingvild Johanne Haug, Steinar Johan Engelsen, Tore Seternes, Magnus N. Hattrem
-
Patent number: 8558028Abstract: There is provided a compound having Formula I wherein each of R1, R2, R3, R4, R5, R6, R7, R8 and R9 are independently selected from (a) H, (b) R13, —OC(R13)3, —OCH(R13)2, —OCH2R13, C(R13)3, —CH(R13)2, or —CH2R13 wherein R13 is a halogen; (c) —CN; (d) optionally substituted alkyl, (e) optionally substituted heteroalkyl; (f) optionally substituted aryl; (g) optionally substituted heteroaryl; (h) optionally substituted arylalkyl; (i) optionally substituted heteroarylalkyl; (j) hydroxy; (k) alkoxy; (l) aryloxy; (m) —SO2-alkyl; and (n) —N(R14)C(O)R15, wherein R14 and R15 are independently selected from H and hydrocarbyl, wherein the optional substituents of (d) (e) (f) (h) and (i) are selected from the group consisting of: C1-6 alkyl, halo, cyano, nitro, haloalkyl, hydroxy, C1-6 alkoxy, carboxy, carboxyalkyl, carboxamide, mercapto, amino, alkylamino, dialkylamino, sulfonyl, sulfonamido, aryl and heteroaryl; wherein n and p are independently selected from 0 and 1; X is an optional group selected from O, S, S=0Type: GrantFiled: November 19, 2008Date of Patent: October 15, 2013Assignee: University of Bath of Claverton DownInventors: Nigel Vicker, Helen Victoria Bailey, Wesley Heaton, Joanna Mary Day, Atul Purohit, Barry Victor Lloyd Potter
-
Publication number: 20130244985Abstract: Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least analgesic and/or at least one anti-inflammatory agent at or near a target site, one can reduce, prevent or treat inflammation and pain.Type: ApplicationFiled: May 10, 2013Publication date: September 19, 2013Applicant: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Publication number: 20130225596Abstract: The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect. A pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect comprising a compound of the formula (I): wherein ring A is substituted or unsubstituted 5 to 7-membered cycloalkane, substituted or unsubstituted 5 to 7-membered cycloalkene or the like; C is a carbon atom; —X— is —N(R16)— or the like; R16 is hydrogen, substituted or unsubstituted alkyl or the like; R7 is substituted or unsubstituted 5- or 6-membered heteroaryl, substituted or unsubstituted 6 to 10 membered aryl; Q1 and Q2 are each independently a carbon atom or a nitrogen atom; -L- is —O—, —S— or the like; R6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl or the like; R2 is hydrogen, hydroxy or the like, or its pharmaceutically acceptable salt or a solvate thereof.Type: ApplicationFiled: August 9, 2011Publication date: August 29, 2013Inventors: Hiroyuki Kai, Takeshi Endoh, Sae Jikihara, Kentaro Asahi, Tohru Horiguchi
-
Publication number: 20130217779Abstract: The present invention relates to a method for treating drug addiction or neuropathic pain in a patient known to be vulnerable to life threatening cardiac arrhythmias (e.g., abnormally prolonged QT intervals, potassium chanelopathies, hypokalemia, or a combination thereof) by administering the R isolate of methadone to the patient.Type: ApplicationFiled: June 20, 2012Publication date: August 22, 2013Applicant: ACADEMIC PHARMACEUTICALS INCORPORATEDInventors: John C. Somberg, Vasant Ranade
-
Publication number: 20130195957Abstract: A patch comprising a support and an adhesive agent layer, wherein the adhesive agent layer comprises at least one selected from the group consisting of tolterodine acetate and salts thereof.Type: ApplicationFiled: July 27, 2011Publication date: August 1, 2013Applicant: HISAMITSU PHARMACEUTICAL CO., INC.Inventors: Tomohiro Shinoda, Naoyuki Uchida, Yasunori Takada
-
Publication number: 20130196849Abstract: The present invention relates to substituted cellulose acetates and methods of use thereof. One embodiment of the present invention provides a coating having a substituted cellulose acetate having a polar substituent that has an oxygen atom covalently bonded to a nonmetal selected from the group of sulfur, phosphorus, and boron; wherein the nonmetal is present in at least about 0.01% by weight of the substituted cellulose acetate.Type: ApplicationFiled: January 27, 2012Publication date: August 1, 2013Applicant: Celanese Acetate LLCInventors: Michael T. Combs, Thomas S. Garrett
-
Publication number: 20130190237Abstract: A method for aiding in categorising or determining prognosis in a patient with cancer, for example breast cancer (or, for example, hepatocellular, bladder or gastric cancer) or in selecting a therapeutic strategy for a patient with cancer, for example breast cancer (or, for example, hepatocellular, bladder or gastric cancer), the method comprising the step of assessing the level of LMTK3 nucleic acid, protein or activity in a sample obtained from the patient and/or assessing the patient's genotype for LMTK3, optionally at position rs8108419 (in intron 2 of the LMTK3 gene) and/or position rs9989661 (in intron 15 of the LMTK3 gene). The method may further comprise the step of assessing the level of ERa nucleic acid, protein or activity in a sample obtained from the patient, particularly in the case of breast cancer.Type: ApplicationFiled: April 6, 2011Publication date: July 25, 2013Applicant: IMPERIAL INNOVATIONS LIMITEDInventors: Georgios Giamas, Justin Stebbing
-
Publication number: 20130184279Abstract: Compounds of formula Ia and Ib wherein A, B, C, R1 and R14 are described herein.Type: ApplicationFiled: December 18, 2012Publication date: July 18, 2013Applicant: Bristol-Myers Squibb CompanyInventor: Bristol-Myers Squibb Company
-
Patent number: 8486452Abstract: A pharmaceutical composition contains tolterodine L-tartrate stabilized against degradation with an acid. Acid-stabilized tolterodine L-tartrate may be used to make various types of immediate release and controlled release dosage forms.Type: GrantFiled: July 20, 2007Date of Patent: July 16, 2013Assignee: Mylan Pharmaceuticals Inc.Inventors: David T. Rossi, Boyong Li, James Paul McCall
-
Publication number: 20130171091Abstract: Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.Type: ApplicationFiled: January 18, 2013Publication date: July 4, 2013Applicant: Massachusetts Institute of TechnologyInventor: Massachusetts Institute of Technology
-
Publication number: 20130171256Abstract: This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing venlafaxine or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.Type: ApplicationFiled: May 9, 2011Publication date: July 4, 2013Applicant: CIMA LABS Inc.Inventor: Ehab Hamed